]>
IRCT20201015049036N1 IRCT 2020-11-27 Dezfoul University of Medical Sciences Efficacy of Date Palm Leaf Extract (Phoenix dactylifera) in Patients with COVID-19 Hospitalized in Ganjavian Hospital in Dezful Efficacy of Palm Leaf Extract (Phoenix dactylifera) in Patients with COVID-19 Patients Admitted to Ganjavian Hospital in Dezful with Mild to Moderate Stages: A Randomized Clinical Trial 2020-09-12 anticipated 100 Complete https://irct.ir/trial/51772 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: The study will be conducted in cooperation with infectious and internal specialists and pulmonary specialists, Randomization description: Patients with inclusion criteria and with respect to their genders will be assessed clinically. The patients will be divided into to two groups randomly: drug recipients and placebo recipients. The patients will be assigned certain codes, and only the pharmacy team will be aware of the nature of the two groups. The physician in chief, the nurses and the patients are not aware of whether they are receiving drug or placebo.placebo of the syrup, Blinding description: Patients use drugs and placebo that are in exactly the same containers and labels but have different codes, and except for the pharmacy team, none of the treating physicians, nurses, and patients are aware of those codes. 2 Coronavirous (COVID19). Intervention 1: Intervention group: treatment- medicine: Phoenix medicine (contains hydro alcoholic solution, Phoenix leaf extract, Vitamin C and Strawberry flavoring) 5 times/day, each time 5 ml. Intervention 2: Control group: treatment-placebo: contains hydro alcoholic solution, Vitamin C , Strawberry flavoring, without Phoenix leaf extract) 5 times/day, each time 5 ml. Yes - There is a plan to make this available What will be shared: The data will be collected by an epidemiologist's cooperation after the jamming. When: Two months. To whom: Dr Gholamreza Amin , Ghasem TakdehghanØ› Dr. Mohammad Dorchin Conditions: Only for data collection and analysis. Where to obtain: Dr. Mohammad Dorchin How to obtain: Written request and approval of the project's executive and the main colleagues of the project (Dr. Gholamreza Amin and Mr. Ghasem Takdehghan) Comments:
public Mohammad Dorchin
No.440 west Farhang 2 Ave.
Dezful Iran (Islamic Republic of) 6461896973 +98 61 4255 6011 dr.dorchin@gmail.com Dezfoul University of Medical Sciences scientific Mohammad Dorchin
No.440 west Farhang2 Ave.
Dezful Iran (Islamic Republic of) 6461896973 +98 61 4255 6011 dr.dorchin@gmail.com Dezfoul University of Medical Sciences Iran (Islamic Republic of) Patients >12 years of age (male/female) with mild to moderate disease, which can be determined by clinical criteria (dry cough, fever and dyspnea) and paraclinical indices PO2, PCR, CT Scan, CRP, CBC Signing the form of consent by persons >18 years of age or the guardians of the under-aged patients 12 years 80 years Both Dissatisfaction of patients or the patients' guardians Any allergic reactions from the use of the palm extract Critically ill patients or the cases where the physician in chief may not recommend this intervention for hospitalized patients U07.1 Corona virus infection, unspecified Treatment - Drugs Placebo Intervention group: treatment- medicine: Phoenix medicine (contains hydro alcoholic solution, Phoenix leaf extract, Vitamin C and Strawberry flavoring) 5 times/day, each time 5 ml. Control group: treatment-placebo: contains hydro alcoholic solution, Vitamin C , Strawberry flavoring, without Phoenix leaf extract) 5 times/day, each time 5 ml. Lung infection. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: CT Scan. Virus diagnosis. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: PCR. Fever. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Thermometer. PaO2: oxygen pressure in arterial blood. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Record the degree of oxygen pressure. CRP: reactive protein in blood for detect the inflammation. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test. ESR: erythrocyte sedimentation rate used to monitor inflammatory diseases. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test. WBC: white blood cell. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test. University Approved 2020-10-06 Ethics Committee Dezful University of Medical Sciences Vice Chancellor for rsearch, Dezful University of Medical Sciences, Azadegan alley, Andimeshk road to Dezful Dezful Khouzestan Iran (Islamic Republic of)